Neoadjuvant anti-PD-1 is named as a drug or biological intervention in 2 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Shanghai Chest Hospital (1) and Shanghai Zhongshan Hospital (1). Registered phases: Phase 2 and Observational. Conditions studied include Esophageal Cancer; Esophageal Squamous Cell Carcinoma; Neoadjuvant Chemoimmunotherapy.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06385730 | Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS) (ClinicalTrials.gov ↗) Esophageal Cancer |
Phase 2 | Recruiting |
| NCT05740995 | Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (ClinicalTrials.gov ↗) Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy |
Observational | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Esophageal Cancer | 1 |
| Esophageal Squamous Cell Carcinoma | 1 |
| Neoadjuvant Chemoimmunotherapy | 1 |
| Lead sponsor | Trials |
|---|---|
| Shanghai Chest Hospital | 1 |
| Shanghai Zhongshan Hospital | 1 |
| Register | Neoadjuvant anti-PD-1 trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Neoadjuvant anti-PD-1 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Neoadjuvant anti-PD-1 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.